Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [619]

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related...

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Rusfertide shows promise for polycythemia vera treatment

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide shows promise for polycythemia vera treatment ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy...

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )

Darolutamide plus ADT provides deep and durable PSA responses in metastatic...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive...

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Everolimus plus lanreotide might be a new standard treatment in the first-line...

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

More from ecancer